Document is current
Any future updates will be listed below
-
Authors
Ohtani, Tomoko
Kuroda, Shinji
Kanaya, Nobuhiko
Kakiuchi, Yoshihiko
Kumon, Kento
Hashimoto, Masashi
Yagi, Chiaki
Sugimoto, Ryoma
Kikuchi, Satoru
Kagawa, Shunsuke
Tazawa, Hiroshi
Urata, Yasuo
Fujiwara, Toshiyoshi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP16K19893)
Japan Agency for Medical Research and Development (17ck0106285)
Okayama University
- License Information
-
More Information
Article History
Received: 30 June 2024
Accepted: 27 September 2024
First Online: 5 November 2024
Declarations
:
: Yasuo Urata is President & CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-301 and OBP-702. Hiroshi Tazawa and Toshiyoshi Fujiwara are consultants of Oncolys BioPharma, Inc. The other authors have no potential conflicts of interest to disclose.
